Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CPTX-2309 in Rheumatoid Arthritis: NCT06917742 Clinical Landscape Report 2026
15 October 2026
NCT06917742 clinical landscape for Rheumatoid Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19/BCMA CAR T-cells(Shanghai Xiniao Biotechnology) in Lupus Nephritis: NCT06920433 Clinical Landscape Report 2026
15 October 2026
NCT06920433 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DXC-008 in Prostatic Cancer: NCT06926283 Clinical Landscape Report 2026
15 October 2026
NCT06926283 clinical landscape for Prostatic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Loncastuximab tesirine in Large B-cell lymphoma: NCT06919939 Clinical Landscape Report 2026
15 October 2026
NCT06919939 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT06921044 Clinical Landscape Report 2026
15 October 2026
NCT06921044 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Loncastuximab tesirine in High grade B-cell lymphoma: NCT06918912 Clinical Landscape Report 2026
15 October 2026
NCT06918912 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Endometrial Carcinoma: NCT06925724 Clinical Landscape Report 2026
15 October 2026
NCT06925724 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zugocaptagene Geleucel in Idiopathic Inflammatory Myopathies: NCT06925542 Clinical Landscape Report 2026
15 October 2026
NCT06925542 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
SHR-A1912 in Diffuse large B-cell lymphoma recurrent: NCT06929624 Clinical Landscape Report 2026
15 October 2026
NCT06929624 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Izalontamab Brengitecan in Triple Negative Breast Cancer: NCT06926868 Clinical Landscape Report 2026
15 October 2026
NCT06926868 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in Advanced Triple-Negative Breast Carcinoma: NCT06926920 Clinical Landscape Report 2026
15 October 2026
NCT06926920 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
OZ-001 in Liver metastases: ACTRN12625000312448 Clinical Landscape Report 2026
15 October 2026
ACTRN12625000312448 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.